PRLD Prelude Therapeutics Incorporated

NASDAQ
$3.88

Prelude Therapeutics Incorporated (PRLD) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -21.7% since its last earnings release on August 11, 2026.

Prelude Therapeutics Beat Consensus Estimates
Tuesday, August 11, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.16)
Rev est $5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.40

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. It is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorporated is based in Wilmington, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.